\u00a0(in million euros)<\/em> <\/td>\n| H1 2019<\/strong> <\/td>\n | H1 2018<\/strong> <\/td>\n | % <\/em><\/strong> | change<\/em><\/strong> <\/td>\n % Variation at constant currency and <\/em><\/strong> | consolidation scope 1<\/sup><\/em><\/strong> <\/td>\n<\/tr>\n Group net sales<\/strong> <\/td>\n | 1,229.6 <\/td>\n | 1,064.5 <\/td>\n | +15.5% <\/td>\n | +14.3% <\/td>\n<\/tr>\n | Specialty Care sales <\/td>\n | 1,100.0 <\/td>\n | 920.2 <\/td>\n | +19.5% <\/td>\n | +16.9% <\/td>\n<\/tr>\n | Consumer Healthcare sales <\/td>\n | \u00a0129.6 <\/td>\n | 144.3 <\/td>\n | -10.2% <\/td>\n | -3.7% <\/td>\n<\/tr>\n | \u00a0 <\/td>\n | \u00a0 <\/td>\n | \u00a0 <\/td>\n | \u00a0 <\/td>\n | \u00a0 <\/td>\n<\/tr>\n | CORE <\/td>\n | \u00a0 <\/td>\n | \u00a0 <\/td>\n | \u00a0 <\/td>\n | \u00a0 <\/td>\n<\/tr>\n | Core Operating Income<\/strong> <\/td>\n | 387.5<\/strong> <\/td>\n | 322.5<\/strong> <\/td>\n | +20.1%<\/em><\/strong> <\/td>\n | \u00a0 <\/td>\n<\/tr>\n | Core Operating margin <\/em>(<\/em>as a %<\/em> net sales)<\/em> <\/td>\n | 31.5%<\/em> <\/td>\n | 30.3%<\/em> <\/td>\n | +1.2 pts<\/em> <\/td>\n | \u00a0 <\/td>\n<\/tr>\n | Core consolidated net profit<\/strong> <\/td>\n | 283.0\u00a0\u00a0 <\/strong> <\/td>\n | 237.1<\/strong> <\/td>\n | +19.3%<\/em><\/strong> <\/td>\n | \u00a0 <\/td>\n<\/tr>\n | Core EPS \u2013 fully diluted (\u20ac) <\/td>\n | 3.38\u00a0\u00a0 <\/td>\n | 2.86 <\/td>\n | +18.5%<\/em> <\/td>\n | \u00a0 <\/td>\n<\/tr>\n | \u00a0 <\/td>\n | \u00a0 <\/td>\n | \u00a0 <\/td>\n | \u00a0 <\/td>\n | \u00a0 <\/td>\n<\/tr>\n | IFRS <\/td>\n | \u00a0 <\/td>\n | \u00a0 <\/td>\n | \u00a0 <\/td>\n | \u00a0 <\/td>\n<\/tr>\n | Operating Income<\/strong> <\/td>\n | 317.8<\/strong> <\/td>\n | 269.7<\/strong> <\/td>\n | +17.8%<\/em><\/strong> <\/td>\n | \u00a0 <\/td>\n<\/tr>\n | \u00a0\u00a0 Operating margin <\/em>(<\/em>as a %<\/em> net sales)<\/em> <\/td>\n | 25.8% <\/td>\n | 25.3% <\/td>\n | +0.5 pts<\/em> <\/td>\n | \u00a0 <\/td>\n<\/tr>\n | Consolidated net profit<\/strong> <\/td>\n | 220.6<\/strong> <\/td>\n | 197.3<\/strong> <\/td>\n | +11.8%<\/em><\/strong> <\/td>\n | \u00a0 <\/td>\n<\/tr>\n | \u00a0\u00a0 EPS \u2013 fully diluted (\u20ac) <\/td>\n | 2.64 <\/td>\n | 2.38 <\/td>\n | +10.9%<\/em> <\/td>\n | \u00a0 <\/td>\n<\/tr>\n<\/table>\n | David Meek, Chief Executive Officer of Ipsen<\/b>, stated:\u00a0\u201cIn the first half of 2019, the strong operational execution of our growth strategy led to robust double-digit sales growth, continued Core Operating margin expansion and an upgrade in our sales guidance for full year 2019. The value of our pipeline was further strengthened by the closing of the Clementia acquisition and promising interim Phase 2 data for Onivyde in first-line pancreatic cancer. Going forward, we will continue to advance our strategic priorities to deliver sustained top-line, bottom-line and pipeline growth.<\/em>\u201d<\/em><\/p>\n Upgraded Full Year 2019 guidance<\/u><\/b><\/p>\n <\/p>\n Q2 2019 Pipeline highlights<\/u><\/b><\/p>\n H1 2019 Financial highlights<\/u><\/b><\/p>\n IFRS operating margin at 25.8% of net sales, up 0.5 points and IFRS Operating Income growth of 17.8%.<\/p>\n Refinancing update<\/u><\/b><\/p>\n First issuance in the private placement market and in the U.S. debt market for the company, illustrating the high level of confidence of investors in Ipsen and in the quality of its credit profile.<\/p>\n The transaction in this press release is not an offer for sale of the securities in the United States. No public offering of the securities will be made in the United States. The securities have not been registered under the U.S. Securities Act of 1933, as amended (the \u201cSecurities Act\u201d), and may not be sold in the United States absent registration or an exemption from registration under the Securities Act.<\/em><\/p>\n Review of the first half 2019 results<\/u><\/b> I<\/strong>FRS Operating Income<\/b>\u00a0was \u20ac317.8 million after amortization of intangible assets and higher Other operating expenses, mainly related to Clementia integration costs and costs arising from the Group\u2019s transformation programs. Operating Income margin of 25.8% is up 0.5 points compared to the first half of 2018. The company\u2019s auditors performed a limited review of the accounts.<\/p>\n The interim financial report, with regard to regulated information, is available on the Group\u2019s website,\u00a0<\/em>www.ipsen.comunder<\/em> the Regulated Information tab in the Investor Relations section.<\/em><\/p>\n Conference call<\/b> \u00a0<\/p>\n |
<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"template":"","categories":[],"tags":[],"class_list":["post-3688","press_release","type-press_release","status-publish","hentry","entry"],"acf":[],"yoast_head":"\n